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Over the past several years, leading experts from around the world have been gatheringannually in Santa Monica, CA, to discuss strategies for improving the outcomes of
patients with lung cancer using molecularly targeted therapies. In contrast to the annual
meeting of the American Society of Clinical Oncology or American Association of Cancer
Research, this is a large “work in progress” meeting. As we are beginning to unravel the
bewildering and complex network of dysregulated pathways in cancer in lung cancer, annual
conferences similar to the one held in Santa Monica have become indispensable to generate
novel ideas and exchange valuable experience gleaned from ongoing studies. A formidable
number of agents, summarized by Drs. George Simon and Neeta Somaiah, are being studied
in lung cancer today. Keeping up with the constant flow of new information is a challenge even
for the very committed student of lung cancer. As the attendance is limited (and by invitation
only), we feel that the larger thoracic oncology community would benefit from an enduring
material from the “Santa Monica Meeting.” The contributors were asked to provide only very
brief succinct summaries and limit references and figures to a bare minimum. The articles in
this supplement should be viewed more as meeting reports than as exhaustive and compre-
hensive review articles. We hope you, the readers of the Journal of Thoracic Oncology, will
find the supplement instructive and useful. The thoracic oncology community owes a debt of
gratitude to the leadership of Drs. Paul Bunn, David Johnson, and Roy Herbst for conceiving
and organizing this “Santa Monica Meeting” year after year.
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